story of the week
Safety and Efficacy of Satralizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Satralizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder: A Randomised, Double-Blind, Multicentre, Placebo-Controlled Phase 3 Trial
Lancet Neurol 2020 May 01;19(5)402-412, A Traboulsee, BM Greenberg, JL Bennett, L Szczechowski, E Fox, S Shkrobot, T Yamamura, Y Terada, Y Kawata, P Wright, A Gianella-Borradori, H Garren, BG WeinshenkerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.